- Conditions
- Muscle Loss, Obesity
- Interventions
- Enobosarm, Semaglutide
- Drug
- Lead sponsor
- Veru Inc.
- Industry
- Eligibility
- 60 Years to 100 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Cullman, Alabama • San Diego, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 127
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alcohol Use Disorder
- Interventions
- Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Havre de Grace, Maryland
- Conditions
- Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
- Interventions
- Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide
- Behavioral · Drug
- Lead sponsor
- Noom Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Multiple Sclerosis
- Interventions
- NLY01, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Type 2 Diabetes
- Interventions
- AZD0186, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
- Interventions
- Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
- Behavioral · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Crohn Disease
- Interventions
- Tirzepatide, Mediterranean diet
- Drug · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- GLP - 1
- Interventions
- Digital Lifestyle Coaching Program
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Obesity
- Interventions
- Medically tailored meals, Noom®, Usual care
- Other · Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 2 Diabetes, Obesity, Bariatric Surgery
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes, Gastric Content Aspiration, Glucagon-like Peptide 1, GLP-1
- Interventions
- Gastric Ultrasound
- Diagnostic Test
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
- Interventions
- Gastric Fundal Mucosal Ablation (GFMA)
- Device
- Lead sponsor
- Dr. Christopher McGowan
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cary, North Carolina
- Conditions
- Obesity, Overweight
- Interventions
- Ribupatide, Placebo
- Drug
- Lead sponsor
- Kailera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 24
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 21 more
- Conditions
- Pre-diabetes, Type 2 Diabetes
- Interventions
- Exenatide, Sitagliptin, Glimepiride
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pregnant Individuals, Obesity & Overweight, Gestational Weight Gain
- Interventions
- Not listed
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Overweight and Obesity, Healthy
- Interventions
- NG101, Placebo, Semaglutide Injectable Product
- Drug
- Lead sponsor
- Neurogastrx, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Interventions
- RDX-002, Placebo
- Drug
- Lead sponsor
- Response Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Semaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,879 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
- Conditions
- End Stage Renal Disease, Renal Impairment, Obesity, Overweight
- Interventions
- Ribupatide
- Drug
- Lead sponsor
- Kailera
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas
- Conditions
- Laxity; Skin
- Interventions
- On GLP1 plus HRT, On GLP1 Only
- Drug
- Lead sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
- Other
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- GLP - 1, Bowel Preparation for Colonoscopy
- Interventions
- Continue GLP/GIP
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Cleveland, Florida • Weston, Florida
- Conditions
- Hyperglycemia, Hypoglycemia
- Interventions
- GLP 1, normal saline solution placebo
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania